Photobiomodulation (PBM) is a process that uses light, with nondestructive and nonthermal delivery techniques, to modulate mitochondrial respiration and cellular functions in many cell types, including neurons.1–4 PBM has also been called low-level laser (light) therapy (LLLT), when its goal is to serve as a therapy for a variety of medical conditions, such as for pain relief and wound healing.5,6 When PBM is aimed at the human head, the term transcranial photobiomodulation (tPBM) has been used to emphasize that the target modulated by light is the human cerebral cortex, up to below the human scalp,7 with the goal of enhancing cerebral oxygenation and cognitive functioning.8–10 In general, most research studies or clinical applications with tPBM have utilized either lasers or light-emitting diodes (LEDs) in the red (620 to 680 nm) or near-infrared (800 to 980 nm) spectral range.11 LEDs with a bandwidth of 1064 to 1080 nm were applied to neuromodulate the human brain of a small group of dementia patients (six active, three controls, and two dropouts) and to demonstrate the feasibility of tPBM being able to improve the patients’ executive functioning.12 This study also reports a trend of tPBM-induced improvement in electroencephalogram (EEG) amplitude and connectivity. Furthermore, a 1064-nm infrared laser has been utilized to apply tPBM and is reported to improve cognitive performance on various tasks in sham-controlled studies with more than 300 human subjects.13–16 More recently, we have demonstrated that tPBM by 1064-nm laser induced significant changes in cerebral blood oxygenation as measured with functional near-infrared spectroscopy.17,18 These changes are caused by neuron–photon interaction that induces increases in the concentration of oxidized cytochrome-c-oxidase (CCO),18 the enzyme at the terminal stage of the mitochondrial respiratory chain.19
Transcranial magnetic stimulation (TMS) is a non-invasive tool to perturb brain activity. In TMS studies, the stimulation intensity (SI) is commonly normalized to the resting motor threshold (rMT) that produces muscle responses in 50% of stimulations applied to the motor cortex (M1). Since rMT is influenced by spinal excitability and coil-to-cortex distance, responses recorded from the cortex, instead of a peripheral muscle, could provide a more accurate marker for cortical excitability. Combining TMS with electroencephalography (EEG) enables the measurement of brain-wide cortical reactivity to TMS. We quantified TMS-induced changes in oscillatory power and phase of EEG with event-related spectral perturbation (ERSP) and inter-trial coherence (ITC). We studied the SI-dependency of ERSP and ITC responses by stimulating the dominant M1 of 10 healthy volunteers using single-pulse TMS with 150 pulses at 60%, 80%, 100% and 120% of rMT. We found SI-dependent ERSP and ITC responses in M1, most notably with the wide-band (8–70Hz) early ITC responses averaged 20–60ms after TMS. With approximately linear SI-dependence, the early ITC response was consistent between SIs (intraclass correlation= 0.78, p < 0.001). Our results reveal the potential of oscillatory EEG responses, in place of rMT, as a measure of the cortical excitability threshold in M1.
Transcranial magnetic stimulation (TMS) is a non-invasive technique to stimulate the brain, while electroencephalography (EEG) is a non-invasive technique to record its electrical activity. Their combined use (TMS-EEG) has been established only relatively recently, after successful development of TMS-compatible EEG amplifiers. TMS-EEG offers the unparalleled opportunity to directly perturb the brain with TMS and simultaneously record its response with EEG. This allows inferences on causal input-output relationships, therefore going critically beyond purely observational techniques, such as resting-state EEG or functional MRI, in the study of brain dynamics. This consensus review updates the work of Tremblay and coworkers [Clin Neurophysiol 2019; 130: 802-844]. Since then, substantial advances have been made in understanding contamination of TMS-EEG signals by physiological and non-physiological artifacts, as well as in developing strategies to avoid or control them. In parallel, new insights have emerged regarding the physiological mechanisms underlying TMS-EEG responses and their diagnostic and prognostic utility in a broad range of psychiatric and neurological disorders. As such, TMS-EEG is rapidly shaping a dynamic new field in clinical neurophysiology and neuroscience. This review provides a critical and comprehensive synthesis of current knowledge, including practical guidance for implementing TMS-EEG in the clinical setting.